CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Innovations in API Manufacturing of Small Molecule Drugs

Throughout the years, innovation has been the driving factor of many industries, allowing them to stay viable. This is also the case for the pharmaceutical industry, including API manufacturing. With the cost of new pharmaceuticals steadily rising, innovation is the only way to reduce it and ensure the future availability of new pharmaceutical treatments. Predicting which fine chemicals or APIs will be significant in the following decades is also challenging. Only through innovation is the industry capable of reacting in time to fulfil the market’s needs. This article discusses recent and future innovations in the API manufacturing industry with the potential of reducing manufacturing costs and addressing market demand accurately.

Introduction
Innovation is the practical implementation of ideas that results in introducing new goods or services or improving the offerings of existing goods or services. ISO TC 279 in the standard ISO 56000:2020 defines innovation as “a new or changed entity, realising or redistributing value”. Others have different definitions, but a common element is the focus on newness, improvement, and the spread of ideas or technologies.

The pharmaceutical industry, and therefore also the manufacturing of APIs, faces many hurdles, including the availability of a skilled workforce, supply chain disruptions, the rising cost of new therapies, and increasing environmental regulations. Innovation is the only way to decrease costs and secure the future availability of new pharmaceutical treatments. Predicting which fine chemicals or APIs will be significant in the following decades is also challenging. Only through innovation is the industry capable of reacting in time to fulfil the market’s needs.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026